BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 16712673)

  • 1. The relationship between four single nucleotide polymorphisms in the promoter region of the osteoprotegerin gene and aortic calcification or coronary artery disease in Koreans.
    Rhee EJ; Oh KW; Jung CH; Lee WY; Oh ES; Yun EJ; Baek KH; Kang MI; Kim SW
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):689-97. PubMed ID: 16712673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects.
    Anand DV; Lahiri A; Lim E; Hopkins D; Corder R
    J Am Coll Cardiol; 2006 May; 47(9):1850-7. PubMed ID: 16682312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women.
    Kim JG; Kim JH; Kim JY; Ku SY; Jee BC; Suh CS; Kim SH; Choi YM
    Menopause; 2007; 14(5):913-8. PubMed ID: 17667143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteoprotegerin (OPG)/RANK-L system in juvenile idiopathic arthritis: is there a potential modulating role for OPG/RANK-L in bone injury?
    Masi L; Simonini G; Piscitelli E; Del Monte F; Giani T; Cimaz R; Vierucci S; Brandi ML; Falcini F
    J Rheumatol; 2004 May; 31(5):986-91. PubMed ID: 15124262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum levels of osteoprotegerin and osteoprotegerin polymorphisms in Gaucher disease.
    Magal I; Lebel E; Altarescu G; Itzchaki M; Rudensky B; Foldes AJ; Zimran A; Elstein D
    Br J Haematol; 2006 Apr; 133(1):93-7. PubMed ID: 16512834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction.
    Crisafulli A; Micari A; Altavilla D; Saporito F; Sardella A; Passaniti M; Raffa S; D'anneo G; Lucà F; Mioni C; Arrigo F; Squadrito F
    Clin Sci (Lond); 2005 Oct; 109(4):389-95. PubMed ID: 15926884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of C161-->T polymorphisms in exon 6 of peroxisome proliferator-activated receptor-gamma gene on bone mineral metabolism and serum osteoprotegerin levels in healthy middle-aged women.
    Rhee EJ; Oh KW; Lee WY; Kim SY; Oh ES; Baek KH; Kang MI; Kim SW
    Am J Obstet Gynecol; 2005 Apr; 192(4):1087-93. PubMed ID: 15846185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins.
    Abrahamsen B; Hjelmborg JV; Kostenuik P; Stilgren LS; Kyvik K; Adamu S; Brixen K; Langdahl BL
    Bone; 2005 Apr; 36(4):727-35. PubMed ID: 15781001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic polymorphisms of OPG, RANK, and ESR1 and bone mineral density in Korean postmenopausal women.
    Choi JY; Shin A; Park SK; Chung HW; Cho SI; Shin CS; Kim H; Lee KM; Lee KH; Kang C; Cho DY; Kang D
    Calcif Tissue Int; 2005 Sep; 77(3):152-9. PubMed ID: 16151677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum osteoprotegerin levels and the extent of vascular calcification in haemodialysis patients.
    Nitta K; Akiba T; Uchida K; Otsubo S; Takei T; Yumura W; Kabaya T; Nihei H
    Nephrol Dial Transplant; 2004 Jul; 19(7):1886-9. PubMed ID: 15128884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A single nucleotide polymorphism in the promoter region of the osteoprotegerin gene is related to intima-media thickness of the carotid artery in hypertensive patients. The Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA).
    Brändström H; Stiger F; Kahan T; Melhus H; Nyström F; öHman KP; Malmqvist K; Lind L; Kindmark A
    Blood Press; 2004; 13(3):152-7. PubMed ID: 15223723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteoprotegerin gene polymorphisms in men with coronary artery disease.
    Soufi M; Schoppet M; Sattler AM; Herzum M; Maisch B; Hofbauer LC; Schaefer JR
    J Clin Endocrinol Metab; 2004 Aug; 89(8):3764-8. PubMed ID: 15292302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients.
    Kraj M; Owczarska K; Sokołowska U; Centkowski P; Pogłód R; Kruk B
    Arch Immunol Ther Exp (Warsz); 2005; 53(5):454-64. PubMed ID: 16314829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of the osteoprotegerin gene polymorphisms with bone mineral density in postmenopausal women.
    Arko B; Prezelj J; Kocijancic A; Komel R; Marc J
    Maturitas; 2005 Jul; 51(3):270-9. PubMed ID: 15978970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Bone and bone related biochemical examinations. Bone and collagen related metabolites. Measurement and clinical role of OPG].
    Sasaki N; Kusano E
    Clin Calcium; 2006 Jun; 16(6):956-62. PubMed ID: 16751691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of osteoprotegerin (OPG) gene polymorphism in patients with ischaemic heart disease on the morphology of coronary arteries and bone mineral density.
    Celczyńska Bajew L; Horst Sikorska W; Bychowiec B; Wykrętowicz A; Wesoły J; Michalak M
    Kardiol Pol; 2011; 69(6):573-8. PubMed ID: 21678294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The RANKL/OPG system and bone mineral density in patients with chronic liver disease.
    Moschen AR; Kaser A; Stadlmann S; Millonig G; Kaser S; Mühllechner P; Habior A; Graziadei I; Vogel W; Tilg H
    J Hepatol; 2005 Dec; 43(6):973-83. PubMed ID: 16143421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of the genetic influence of the OPG, VDR (Fok1), and COLIA1 Sp1 polymorphisms on BMD in the Irish population.
    Wynne F; Drummond F; O'Sullivan K; Daly M; Shanahan F; Molloy MG; Quane KA
    Calcif Tissue Int; 2002 Jul; 71(1):26-35. PubMed ID: 12073153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of the osteoprotegerin/receptor activator of nuclear factor-kappa B ligand system in gingival crevicular fluid and tissue of patients with chronic periodontitis.
    Lu HK; Chen YL; Chang HC; Li CL; Kuo MY
    J Periodontal Res; 2006 Aug; 41(4):354-60. PubMed ID: 16827732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low bone density and low serum levels of soluble RANK ligand are associated with severe arterial calcification in patients with Takayasu arteritis.
    Bezerra MC; Calomeni GD; Caparbo VF; Gebrim ES; Rocha MS; Pereira RM
    Rheumatology (Oxford); 2005 Dec; 44(12):1503-6. PubMed ID: 16219645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.